DE69406779T2 - 2-substituierte morpholin- und thiomorpholinderivate als gaba-b antagonisten - Google Patents

2-substituierte morpholin- und thiomorpholinderivate als gaba-b antagonisten

Info

Publication number
DE69406779T2
DE69406779T2 DE69406779T DE69406779T DE69406779T2 DE 69406779 T2 DE69406779 T2 DE 69406779T2 DE 69406779 T DE69406779 T DE 69406779T DE 69406779 T DE69406779 T DE 69406779T DE 69406779 T2 DE69406779 T2 DE 69406779T2
Authority
DE
Germany
Prior art keywords
pct
formula
gaba
antagonists
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69406779T
Other languages
English (en)
Other versions
DE69406779D1 (en
Inventor
Shen-Chun Kuo
David Blythin
William Kreutner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE69406779D1 publication Critical patent/DE69406779D1/de
Publication of DE69406779T2 publication Critical patent/DE69406779T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/121,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533Six-membered rings
    • C07F9/65335Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69406779T 1993-03-26 1994-03-23 2-substituierte morpholin- und thiomorpholinderivate als gaba-b antagonisten Expired - Lifetime DE69406779T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3858493A 1993-03-26 1993-03-26
PCT/US1994/002803 WO1994022843A1 (en) 1993-03-26 1994-03-23 2-substituted morpholine and thiomorpholine derivatives as gaba-b antagonists

Publications (2)

Publication Number Publication Date
DE69406779D1 DE69406779D1 (en) 1997-12-18
DE69406779T2 true DE69406779T2 (de) 1998-03-12

Family

ID=21900746

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69406779T Expired - Lifetime DE69406779T2 (de) 1993-03-26 1994-03-23 2-substituierte morpholin- und thiomorpholinderivate als gaba-b antagonisten

Country Status (14)

Country Link
US (1) US5929236A (de)
EP (1) EP0690850B1 (de)
JP (1) JP2778832B2 (de)
AT (1) ATE160143T1 (de)
AU (1) AU6408894A (de)
CA (1) CA2158952C (de)
DE (1) DE69406779T2 (de)
DK (1) DK0690850T3 (de)
ES (1) ES2109683T3 (de)
GR (1) GR3025950T3 (de)
IL (1) IL109111A (de)
TW (1) TW280817B (de)
WO (1) WO1994022843A1 (de)
ZA (1) ZA942090B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK30198A3 (en) * 1995-09-07 1998-08-05 Novartis Ag Substituted phosphinic compounds and their use as pharmaceuticals
WO1998028313A1 (en) * 1996-12-24 1998-07-02 Novartis Ag (thio)morpholine-substituted carboxylic and phosphinic acids
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス,インコーポレイティド Pde阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド 5ht受容体介在性の神経新生
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889857A (en) * 1987-10-12 1989-12-26 Yoshitomi Pharmaceutical Industries, Ltd. Quinolonecarboxylic acid compounds and pharmaceutical use thereof
NZ233503A (en) * 1989-05-15 1991-06-25 Janssen Pharmaceutica Nv Substituted (thio)morpholinyl and piperazinyl alkylphenol ethers
JPH04270272A (ja) * 1991-02-25 1992-09-25 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法

Also Published As

Publication number Publication date
JPH08503229A (ja) 1996-04-09
CA2158952C (en) 1999-05-18
CA2158952A1 (en) 1994-10-13
DK0690850T3 (da) 1998-02-09
WO1994022843A1 (en) 1994-10-13
ES2109683T3 (es) 1998-01-16
US5929236A (en) 1999-07-27
IL109111A0 (en) 1994-06-24
DE69406779D1 (en) 1997-12-18
EP0690850B1 (de) 1997-11-12
ZA942090B (en) 1994-09-26
TW280817B (de) 1996-07-11
AU6408894A (en) 1994-10-24
ATE160143T1 (de) 1997-11-15
EP0690850A1 (de) 1996-01-10
JP2778832B2 (ja) 1998-07-23
IL109111A (en) 1999-07-14
GR3025950T3 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
KR880012218A (ko) 캘폰 유도체를 사용한 다발성 경화증의 치료방법
ES2150489T3 (es) 1-amidinofenil-pirrolidonas, -piperidinonas, -azetinonas como inhibidores de la agregacion de plaquetas.
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
DE69406779T2 (de) 2-substituierte morpholin- und thiomorpholinderivate als gaba-b antagonisten
RU94044454A (ru) Ингибитор аутоимунных заболеваний
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
ATE174508T1 (de) Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase
PT838223E (pt) Inibidor do edema cerebral
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
KR950701623A (ko) 치환된 헥사하이드로벤조페난트리딘
KR950032171A (ko) 옥소피리디닐퀴녹살린 유도체
DE69315836T2 (de) Pyrazolpyridine für die behandlung der anämie
MX9707596A (es) Benzamidas, el uso de las mismas, composiciones que las contienen, para el tratamiento del transtorno neurodegenerativo, y procedimiento para la preparacion del mismo.
FR2700166B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
TW244336B (de)
SE9702716D0 (sv) Substituted phenylazacycloalkanes in the treatment of cognitive disorders
BR9809313A (pt) Compostos, promedicamento, medicamento, processo para a sua preparação e utilização dos mesmos
ES2138017T3 (es) Uso de n-(piridinil)-1h-indol-1-aminas para la preparacion de un medicamento para el tratamiento de trastornos obsesivo-compulsivos.
DK0632717T3 (da) Middel til anvendelse som et anti-irritationsmiddel
UA66751C2 (en) Benzamides as medicament for treatment of neurodegenerative state, a method for the preparation thereof (variants), pharnaceutical composition for treatment of neurodegenerative states and a method for treatment
MX9304403A (es) Derivados farmacologicamente activos de ó-(aminometilo terciario)-bencenmetanol

Legal Events

Date Code Title Description
8364 No opposition during term of opposition